Adjuvants and Vector Systems for Allergy Vaccines

Immunology and Allergy Clinics of North America

Volumn 31, Issue 2, 2011, Pages 407-419

  Moingeon, Philippe ^a   Lombardi, Vincent ^a   Saint Lu, Nathalie ^a   Tourdot, Sophie ^a   Bodo, Véronique ^a   Mascarell, Laurent ^a  

^a Research and Development   (France)

Author keywords

Adjuvants; Allergy vaccine; Immunopotentiation; Immunotherapy; Mucosal immunity; Vector system

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; ALLERGY VACCINE; ALUMINUM HYDROXIDE; ANTIALLERGIC AGENT; BACTERIAL TOXIN; CALCINEURIN INHIBITOR; CALCIUM PHOSPHATE; CHOLERA TOXIN; CYCLOSPORIN A; DEXAMETHASONE; DIHYDROXYCOLECALCIFEROL; GLUCOCORTICOID; IMIDAZOQUINOLINE DERIVATIVE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; IMMUNOLOGICAL ADJUVANT; LIPOSOME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYGLACTIN; PROBIOTIC AGENT; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; VIROSOME;

ANTIBODY DETECTION; ANTIGEN PRESENTING CELL; ASTHMA; BASOPHIL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ECZEMA; HISTAMINE RELEASE; HUMAN; HUMORAL IMMUNITY; IMMUNOPOTENTIATION; IMMUNOTHERAPY; INSECT ALLERGY; MAST CELL; MUCOSAL IMMUNITY; NANOTECHNOLOGY; NONHUMAN; POLLEN ALLERGY; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PURIFICATION; RESPIRATORY TRACT DISEASE; REVIEW; UPREGULATION; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; DRUG DELIVERY SYSTEMS; HUMANS; HYPERSENSITIVITY; VACCINES;

EID: 79955402717     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2011.03.001     Document Type: Review

References (100)

1. Bousquet J., Lockey R., Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998, 102:558-562.
2. Noon L. Prophylactic inoculation against hay fever. Lancet 1911, 2:1572-1573.
3. Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911, 2:814-817.
4. Cox L., Li J.T., Nelson H.S., et al. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007, 120:25-85.
5. Durham S.R., Walker S.M., Varga E., et al. Long term clinical efficacy of grass pollen immunotherapy. N Engl J Med 1999, 341:468-475.
6. Bousquet J., Van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108:S147-S334.
7. Wilcock L.K., Francis J.N., Durham S.R. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin Exp Allergy 2004, 34:1373-1378.
8. Mascarell L., Van Overtvelt L., Moingeon P. Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines. Immunol Allergy Clin North Am 2006, 26:283-306.
9. Canonica G.W., Bousquet J., Casale T., et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009, 64(Suppl 91):1-59.
10. Wilson D.R., Torres L.I., Durham S.R. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003, 2. CD002893.
11. Passalacqua G., Lombardi C., Troise C., et al. Sublingual immunotherapy: certainties, unmet needs and future directions. Eur Ann Allergy Clin Immunol 2009, 41:163-170.
12. Valenta R., Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007, 119:826-830.
13. Burdin N., Guy B., Moingeon P. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs 2004, 18:79-93.
14. Moingeon P., de Taisne C., Almond J. Delivery technologies for human vaccines. Br Med Bull 2002, 62:29-44.
15. Chapman M.D., Wünschmann S., Pomés A. Protease as Th2 adjuvants. Curr Allergy Asthma Rep 2007, 7:363-367.
16. Trivedi B., Valerio C., Slater J.E. Endotoxin content of standardized allergen vaccines. J Allergy Clin Immunol 2003, 111:777-783.
17. Barret N.A., Maekawa A., Rahman O.M., et al. Dectin-2 recognition of house dust mite triggers cysteinyl leukotriene generation by dendritic cells. J Immunol 2009, 182:1119-1128.
18. Akdis C.A., Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011, 127:18-27.
19. Durham S.R., Till S.J. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998, 102:157-164.
20. Till S.J., Francis J.N., Nouri-Aria K., et al. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004, 113:1025-1034. [quiz: 35].
21. Wachholz P.A., Durham S.R. Induction of 'blocking' IgG antibodies during immunotherapy. Clin Exp Allergy 2003, 33:1171-1174.
22. van Neerven R.J., Wikborg T., Lund G., et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999, 163:2944-2952.
23. Razafindratsita A., Saint-Lu N., Mascarell L., et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007, 120:278-285.
24. Bahceciler N.N., Arikan C., Taylor A., et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005, 136:287-294.
25. Durham S.R., Varney V.A., Gaga M., et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy 1999, 29:1490-1496.
26. Durham S.R., Ying S., Varney V.A., et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996, 97:1356-1365.
27. Moingeon P., Batard T., Fadel R., et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006, 61:151-165.
28. Robinson D.S., Larche M., Durham S.R. Tregs and allergic disease. J Clin Invest 2004, 114:1389-1397.
29. Ebner C., Siemann U., Bohle B., et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997, 27:1007-1015.
30. Jutel M., Akdis M., Budak F., et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003, 33:1205-1214.
31. Francis J.N., Till S.J., Durham S.R. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003, 111:1255-1261.
32. Ciprandi G., Fenoglio D., Cirillo I., et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005, 95:38-44.
33. Bohle B., Kinaciyan T., Gerstmayr M., et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007, 120:707-713.
34. O'Hehir R.E., Gardner L.M., de Leon M.P., et al. House dust mite sublingual immunotherapy. The role for transforming growth factor B and functional regulatory T cells. Am J Respir Crit Care Med 2009, 180:936-947.
35. Allam J.P., Peng W.M., Appel T., et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008, 121:368-374.
36. Allam J.P., Novak N., Fuchs C., et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 2003, 112:141-148.
37. Mascarell L., Lombardi V., Louise A., et al. Oral dendritic cells mediate antigen-specific tolerance by stimulating Th1 and regulatory CD4+ T cells. J Allergy Clin Immunol 2008, 122:603-609.
38. McKee A.S., Munks M.W., Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 2007, 27:687-690.
39. van Overtvelt L., Moussu H., Horiot S., et al. Lactic acid bacteria as adjuvants for sublingual allergy vaccines. Vaccine 2010, 28:2986-2992.
40. Kalliomaki M., Salminen S., Poussa T., et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003, 361:1869-1871.
41. Grangette C., Nutten S., Palumbo E., et al. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci U S A 2005, 102:10321-10326.
42. Smits H.H., Engering A., van der Kleij D., et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 2005, 115:1260-1267.
43. Prescott S.L., Dunstan J.A., Hale J., et al. Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. Clin Exp Allergy 2005, 35:1557-1564.
44. de Roock S., van Elk M., van Dijk M.E., et al. Lactic acid bacteria differ in their ability to induce functional regulatory T cells in humans. Clin Exp Allergy 2010, 40:103-110.
45. Zuany-Amorim C., Manlius C., Trifilieff A., et al. Long-term protective and antigen-specific effect of heat-killed Mycobacterium vaccae in a murine model of allergic pulmonary inflammation. J Immunol 2002, 169:1492-1499.
46. Arikan C., Bahceciler N.N., Deniz G., et al. Bacillus Calmette-Guérin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin Exp Allergy 2004, 34:398-405.
47. Arkwright P.D., David T.J. Effect of Mycobacterium vaccae on atopic dermatitis in children of different ages. Br J Dermatol 2003, 149:1029-1034.
48. Choi I.S., Koh Y.I. Effects of BCG revaccination on asthma. Allergy 2003, 58:1114-1116.
49. Townley R.G., Barlan I.B., Patino C., et al. The effect of BCG vaccine at birth on the development of atopy or allergic disease in young children. Ann Allergy Asthma Immunol 2004, 92:350-355.
50. Smit J.J., Van Loveren H., Hoekstra M.O., et al. Mycobacterium vaccae administration during allergen sensitization or challenge suppresses asthmatic features. Clin Exp Allergy 2003, 33:1083-1089.
51. Arkwright P.D., David T.J. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol 2001, 107:531-534.
52. Freytag L.C., Clements J.D. Mucosal adjuvants. Vaccine 2005, 23:1804-1813.
53. Pizza M., Giuliani M.M., Fontana M.R., et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001, 19:2534-2541.
54. Akdis C.A., Kussebi F., Pulendran B., et al. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur J Immunol 2003, 33:2717-2726.
55. Trujillo-Vargas C.M., Mayer K.D., Bickert T., et al. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses. Clin Exp Allergy 2005, 35:1003-1013.
56. Santeliz J.V., Van Nest G., Traquina P., et al. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002, 109:455-462.
57. Johansen P., Senti G., Martinez Gomez J.M., et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy 2005, 35:1591-1598.
58. Patel M., Xu D., Kewin P., et al. TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells. J Immunol 2005, 174:7558-7563.
59. Goldman M. Toll-like receptor ligands as novel pharmaceuticals for allergic disorders. Clin Exp Immunol 2007, 147:208-216.
60. Lombardi V., van Overtvelt L., Horiot S., et al. The TLR2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy 2008, 38:1819-1829.
61. Mascarell L., Van Overtvelt L., Lombardi L., et al. A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route. Vaccine 2007, 26:108-118.
62. Baldridge J.R., Yorgensen Y., Ward J.R., et al. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 2000, 18:2416-2425.
63. Quarcoo D., Weixler S., Joachim R.A., et al. Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice. Clin Exp Allergy 2004, 34:1314-1320.
64. Drachenberg K.J., Wheeler A.W., Stuebner P., et al. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001, 56:498-505.
65. Mothes N., Heinzkill M., Drachenberg K.J., et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003, 33:1198-1208.
66. Creticos P.S., Schroeder J.T., Hamilton R.G., et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355:1445-1455.
67. Pfaar O., Barth C., Jaschke C., et al. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol 2010, 154:336-344.
68. Asai K., Foley S.C., Sumi Y., et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy increases CD4+CD25+ T cells in the nasal mucosa of subjects with allergic rhinitis. Allergol Int 2008, 57:377-381.
69. Taher Y.A., van Esch B.C., Hofman G.A., et al. 1alpha,25-dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGFβ. J Immunol 2008, 180:5211-5221.
70. Majak P., Rychlik B., Stelmach I. The effect of oral steroids with and without vitamin D3 on early efficacy of immunotherapy in asthmatic children. Clin Exp Allergy 2009, 39:1830-1841.
71. van Overtvelt L., Lombardi V., Horiot S., et al. IL-10 inducing adjuvants enhance sublingual immunotherapy efficacy. Int Arch Allergy Immunol 2008, 145:152-162.
72. de Jong E.C., Vieira P.L., Kalinski P., et al. Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. J Leukoc Biol 1999, 66:201-204.
73. Penna G., Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000, 164:2405-2411.
74. Piemonti L., Monti P., Allavena P., et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999, 162:6473-6481.
75. Wilckens T., De R.R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 1997, 18:418-424.
76. + T regulatory cell suppression of allergen-stimulated CD4CD25 T cells by an IL-10-dependent mechanism. J Allergy Clin Immunol 2004, 114:296-301.
77. de Jonge M.I., Hamstra H.J., Jiskoot W., et al. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. Vaccine 2004, 22:4021-4028.
78. Crameri R., Kündig T.M., Akdis C.A. Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009, 9:568-573.
79. Galvain S., André C., Vatrinet C., et al. Safety and efficacy studies of liposomes in specific immunotherapy. Curr Ther Res 1999, 60:278-294.
80. Sanders M.T., Brown L.E., Deliyannis G., et al. ISCOM-based vaccines: the second decade. Immunol Cell Biol 2005, 83:119-128.
81. Hu K.F., Lovgren-Bengtsson K., Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 2001, 51:149-159.
82. Kim N., Kwon S.S., Lee J., et al. Protective effect of the DNA vaccine encoding the major house dust mite allergens on allergic inflammation in the murine model of house dust mite allergy. Clin Mol Allergy 2006, 4:1-9.
83. Schöll I., Weissenböck A., Förster-Waldl E., et al. Allergen-loaded biodegradable poly(d,l-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model. Clin Exp Allergy 2004, 34:315-321.
84. Jilek S., Walter E., Merkle H.P., et al. Modulation of allergic responses in mice by using biodegradable poly(lactide-co-glycolide) microspheres. J Allergy Clin Immunol 2004, 114:943-950.
85. Edlmayr J., Niespodziana K., Linhart B., et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009, 182:6298-6306.
86. Schmitz N., Dietmeier K., Bauer M., et al. Displaying Fel d 1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 2009, 206:1941-1955.
87. Kündig T.M., Senti G., Schnetzler G., et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006, 117:1470-1476.
88. Senti G., Johansen P., Haug S., et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009, 39:562-570.
89. Boisgerault F., Moron G., Leclerc C. Virus-like particles: a new family of delivery systems. Expert Rev Vaccines 2002, 1:101-109.
90. Saint-Lu N., Tourdot S., Razafindrasita A., et al. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 2009, 64:1003-1013.
91. Gómez S., Gamazo C., San Roman B., et al. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne. J Immunol Methods 2009, 348:1-8.
92. Broos S., Lundberg K., Akagi T., et al. Immunomodulatory nanoparticles as adjuvants and allergen-delivery system to human dendritic cells: implications for specific immunotherapy. Vaccine 2010, 28:5075-5085.
93. Terada T. New therapeutic strategies: a chimeric human-cat fusion protein inhibits allergic reactivity. Clin Exp Allergy 2006, 6:96-100.
94. Gerstmayr M., Ilk N., Jahn-Schmid B., et al. Natural self-assembly of allergen-S-layer fusion proteins is no prerequisite for reduced allergenicity and T cell stimulatory capacity. Int Arch Allergy Immunol 2009, 149:231-238.
95. Jeannin P., Renno T., Goetsch L., et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat Immunol 2000, 1:502-509.
96. Goetsch L., Gonzalez A., Plotnicky-Gilquin H., et al. Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae. Infect Immun 2001, 69:6434-6444.
97. Haicheur N., Benchetrit F., Amessou M., et al. The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. Int Immunol 2003, 15:1161-1171.
98. El Azami El Idrissi M., Ladant D., Leclerc C. The adenylate cyclase of Bordetella pertussis: a vector to target antigen presenting cells. Toxicon 2002, 40:1661-1665.
99. Bonifaz L.C., Bonnyay D.P., Charalambous A., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004, 199:815-824.
100. Hobson P., Barnfield C., Barnes A., et al. Mucosal immunization with DNA vaccines. Methods 2003, 31:217-224.